Biotechnology & Medical Research
Nov 23 (Reuters) - Morphosys AG :Announces that its licensee Janssen has received approval for Tremfya(r) (guselkumab) in Europe for the treatment of moderate-to-severe plaque psoriasis.Says is entitled to royalties on net sales of Janssen's Tremfya.
Nov 23 (Reuters) - XINTELA AB ::Q3 PRETAX LOSS SEK 4.9 MILLION VERSUS LOSS SEK 3.0 MILLION YEAR AGO.
Nov 22 (Reuters) - Aytu Bioscience Inc :Aytu Bioscience Inc files for mixed shelf of upto $100 million - SEC Filing.
Nov 22 (Reuters) - Synergy Pharmaceuticals Inc :CVI Investments Inc reports a 7.9 percent passive stake in Synergy Pharmaceuticals Inc as of November 13, 2017 - SEC Filing.
No related earnings announcements are currently scheduled within the next 7 days.